<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the efficacy and safety of <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) prospectively in <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) patients intolerant or refractory to conventional medical therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) or <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>/IBD unclassified (UC/IBDU) patients intolerant or refractory to conventional medical therapy received MMF (500-2000 mg bid) </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical response was assessed by the Harvey Bradshaw index (HBI) or <z:hpo ids='HP_0002583'>colitis</z:hpo> activity index (CAI) after 2, 6 and 12 mo of therapy, as were steroid usage and adverse effects </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Fourteen patients (9 CD/5 UC/IBDU; 8M/6F; mean age 50.4 years, range 28-67 years) were treated and prospectively assessed for their response to oral MMF </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 11 patients who were not in remission on commencing MMF, 7/11 (63.6%) achieved remission by 8 wk </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 3 patients in remission on commencing MMF maintained their remission </plain></SENT>
<SENT sid="6" pm="."><plain>Ten patients were still on MMF at 6 mo with 9/14 (64.3%) in remission, while of 12 patients followed for 12 mo, 8 were in remission without dose escalation (66.7%) </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients were withdrawn from the MMF due to drug intolerance </plain></SENT>
<SENT sid="8" pm="."><plain>There were no serious adverse events attributed due to the medication </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: MMF demonstrated efficacy in the management of difficult IBD </plain></SENT>
<SENT sid="10" pm="."><plain>MMF appeared safe, well tolerated and efficacious for both short and long-term therapy, without the need for dose escalation </plain></SENT>
<SENT sid="11" pm="."><plain>Further evaluation of MMF comparing it to conventional <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> is required </plain></SENT>
</text></document>